Bevacizumab does not increase the risk of remote relapse in malignant glioma

Annals of Neurology

Volumn 69, Issue 3, 2011, Pages 586-592

  Wick, Antje ^a   Dörner, Nils ^a   Schäfer, Navina ^a   Hofer, Silvia ^b   Heiland, Sabine ^a   Schemmer, Daniela ^a   Platten, Michael ^a   Weller, Michael ^b   Bendszus, Martin ^a   Wick, Wolfgang ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MALE; PHENOTYPE; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RISK;

EID: 79953282797     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22336     Document Type: Article

References (24)

1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
2. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
3. Wick W, Weller M, van den Bent M, Stupp R., Avastin and recurrent malignant gliomas: a European perspective [letter]. J Clin Oncol 2010; 28: e188-e189.
4. Summary minutes of the Oncologic Drugs Advisory Committee, March 31, 2009. Washington, DC: Center for Drug Evaluation and Research, US Food and Drug Administration, 2009.
5. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
6. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-563. (Pubitemid 40017699)
7. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729. (Pubitemid 350086473)
8. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27: 2542-2552.
9. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2008; 92: 149-155.
10. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 6624-6628. (Pubitemid 32896475)
11. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
12. Narayana A, Kelly P, Golfinos JG, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009; 110: 173-180.
13. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779-787.
14. Wen PY, Macdonald DR, Reardon DM, et al. Draft proposal for an updated response assessment criteria for high grade gliomas, Response Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 2010; 28: 1963-1972.
15. Wick W, Stupp R, Beule A-C, et al. A novel tool to analyse MRI recurrence patterns in glioblastoma. Neuro Oncol 2008; 10: 1019-1024.
16. Verhoeff JJC, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009; 9: 444-452.
17. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73: 1200-1206.
18. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009; 91: 329-336.
19. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998. (Pubitemid 29309448)
20. Lucio-Eterovic AK, Piao Y, de Groot JF., Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 4589-4599.
21. Chamberlain MC, Lassman AB, Iwamoto FM., Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2010; 74: 1239-1241.
22. Pope WB, Xia Q, Das A, et al. Patterns of progression in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study [abstract]. Neuro Oncol 2009; 11: 626.
23. Norden AD, Drappatz J, Wen PY., Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008; 7: 1152-1160.
24. Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008; 14: 7068-7073.